| Exhibition Title： |
3rd Annual Predictive In Vitro Models |
| Initiator： |
Hanson Wade |
| Undertaker： |
Hanson Wade |
| Date： |
2012-09-2 |
| Exhibits： |
Boston USA |
| Details： |
Arm yourself with the information you need to direct your in vitro modeling strategy towards enhanced clinical success
With low efficacy and high toxicity accounting for 70% of Phase II and 87% of Phase III clinical attrition, improving predictive in vitro models has never been such a high priority.
The 3rd Annual Developing More Predictive In Vitro Models Summit will showcase a range of new platforms and technologies that address this issue directly. High potential compounds will be prioritized, toxicity mitigated and clinical strategy directed by development and validation of this new breed of in vitro models.
During research for this meeting, your peers asked for an agenda packed full with the latest improvements in established in vitro models and exciting developments in 3D culture, stem cell and lab-on-a-chip technologies. With candid discussion on these issues guaranteed from senior level figures at the FDA, Novartis, Roche, Abbott, Pfizer and many more, this meeting will provide the most valuable strategic learning experience of the year.
Don’t miss out on this chance to go back to the lab with the tools to direct your preclinical and clinical strategy towards improved clinical performance.
Benefits of attending:
Learn how to avoid costly clincial attrition and maximize your ROI by using in vitro modeling to inform swift and accurate decision making at critical junctures in drug development
Find out how harnessing in silico and 3D culture technology will allow you to develop more predictive preclinical models
Get the latest updates on developing a panel of assays to assess hepatotoxicity and highlight potential clinical toxicity
Discover the potential of applying stem cell models to early stage clinical development
Get expert insight into the regulatory requirements to achieve scientific validation of new in vitro models |
|
